MedTrace Logo

Detection of Tumor DNA in Blood Samples From Cancer Patients

NCT02288754 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2019-08-14

No results posted yet for this study

Summary

The aim of this study is to employ genomic detection methodologies to measure the relative amount of tumor nucleic acids in the blood of a cancer patient with diagnosed metastatic disease that is either commencing, currently undergoing or completed cytotoxic chemotherapy treatment. More generally, this approach will allow us to develop a quantitative measure of therapy efficacy via the counting of the relative changes in tumor molecules over the course of treatment.

Conditions

Interventions

DIAGNOSTIC_TEST

Blood test

No intervention except to collect blood for diagnostic test development

Sponsors & Collaborators

  • Lexent Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Haluk Tezcan, MD · Lexent Bio

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2019-11-30
Completion
2020-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02288754 on ClinicalTrials.gov